期刊
IMMUNOLOGICAL REVIEWS
卷 248, 期 -, 页码 23-35出版社
WILEY
DOI: 10.1111/j.1600-065X.2012.01131.x
关键词
interferon; Th17; Th1; autoimmunity; IL-7
类别
资金
- US National Institutes of Health [1K99NS075099-01]
In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-beta are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30-50% of MS patients are non-responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据